Clinical Trial ProgressBRTX-100 received Fast Track designation from the FDA, which could expedite the development process.
Market OpportunityThere is no existing competition in cervical spinal pain among MSCs, potentially making this opportunity larger than lumbar spinal pain.
Safety ProfileNo serious adverse events were reported in the ongoing trial, indicating a positive safety profile for BRTX-100.